Rogers, Brooke G.
Chan, P. A.
Sutten-Coats, C.
Zanowick-Marr, A.
Patel, R. R.
Mena, L.
Goedel, W. C.
Chu, C.
Silva, E.
Galipeau, D.
Arnold, T.
Gomillia, C.
Curoe, K.
Villalobos, J.
Underwood, A.
Sosnowy, C.
Nunn, Amy S.
Funding for this research was provided by:
National Institute of Mental Health (5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, K23MH124539-01A1, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02)
National Institute of Allergy and Infectious Diseases (P30AI042853)
Article History
Received: 2 July 2022
Accepted: 25 July 2023
First Online: 28 August 2023
Declarations
:
: B.G.R. co-leads a Gilead Sciences grant to provide PrEP within the Rhode Island Department of Corrections: #IN-US-276-5463. Dr. Philip Chan is staff at Rhode Island Public Health Institute and consults for Rhode Island Department of Health. Dr. Leandro A. Mena reports the following consultant and research grants from Gilead Sciences, ViiV Healthcare/Glaxo-Smith Kline, Merck, Roche and research grants from TaiMed and Janssen. All other authors declare no competing interests.
: All methods were carried out in accordance with relevant guidelines and regulations. Study procedures were approved by Institutional Review Boards at The Miriam Hospital, The University of Mississippi Medical Center, and Washington University School of Medicine. Written informed consent was obtained from all participants.
: Not applicable.